Osimertinib is a third-generation molecular targeted drug that acts as an EGFR TKI, designed to target both EGFR-sensitising and EGFR T790M resistance mutations. It has demonstrated clinical activity against central nervous system (CNS) metastases and is approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Osimertinib has shown significant benefits over standard first- and second-generation treatments included in the WHO EML for non-small cell lung cancer. The EML committee has called on MPP to explore licensing opportunities for osimertinib . The primary patent on osimertinib is expected to expire in 2032 and has been granted in more than 60 LMICs.

Patent & licence data in LMICs

Acronyms & abbreviations list